StreetInsider.com News Articles

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Inova Technology (INVA) Reiterated at Overweight by Cantor Fitzgerald Post Webinar With CEO, CFO

Fri, 21 Aug 2026 08:35:20 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $34.00 price target on Inova Technology, Inc. (NASDAQ: INVA).

The analyst commented, "We hosted Innoviva for a broad update via webinar this week. The replay provides a great primer on Innoviva's history, as the company evolved from a royalty-only business into a diversified biopharma with a growing Innoviva Specialty Therapeutics (IST) commercial platform and a portfolio of strategic healthcare assets. INVA is profitably growing an underlying commercial business with a >50% CAGR historically, and the stock (~$1.5B market cap) is trading at < 8x TTM revenue (~$212M TTM) with respect to

Innoviva unit's three antibiotics named Prix Galien USA finalists

Tue, 11 Aug 2026 16:06:12 -0400

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that three of its infectious disease drugs — Xacduro, Zevtera, and Nuzolvence — have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category, according to a press release.

The company said this marks the third consecutive year one of its products has been recognized as a finalist by the Galien Foundation. The 2026 award winners are scheduled to be announced at a ceremony on October 29, 2026, in New York City.

Xacduro (sulbactam/durlobactam for injection) was approved by the FDA in May 2023 for

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Tue, 11 Aug 2026 16:05:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics product has been recognized by the renowned Galien Foundation.